Showing 214 results

Filters Content type: News, Editors' picks, About HIV Topic: People with limited treatment options

HIV treatment for people who have a strain of HIV that is resistant to multiple drug classes or who cannot take other HIV medications.

New & experimental HIV treatments

IAS 2021: Injectable treatment for multidrug-resistant HIV Video

July 2021
New & experimental HIV treatments

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy

News
17 July 2021
Pharmaceutical industry

Gilead files long-acting HIV med for patients running out of options

Editor's pick
FierceBiotech
1 July 2021
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options

Editor's pick
Gilead press release
29 June 2021
HIV treatment

Fostemsavir Factsheet

About HIV
April 2021
HIV treatment

Fostemsavir (Rukobia) Detailed information

About HIV
April 2021
People with limited treatment options

Heavily treatment-experienced people in Europe do not have a higher risk of clinical events

News
1 April 2021
New & experimental HIV treatments

HIV capsid inhibitor offers new option for people with highly resistant HIV

News
10 March 2021
New & experimental HIV treatments

ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

Editor's pick
ViiV Healthcare press release
8 February 2021
New & experimental HIV treatments

ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available

Editor's pick
ViiV Healthcare press release
11 December 2020
HIV treatment

Top 10 HIV Clinical Developments of 2020

Editor's pick
TheBodyPro
1 December 2020
New & experimental HIV treatments

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV

Editor's pick
Gilead press release
20 November 2020
New & experimental HIV treatments

Monoclonal antibody ibalizumab maintains HIV suppression for nearly a decade

News
29 October 2020
People with limited treatment options

Patients with HIV and four-class drug resistance have high disease burden

Editor's pick
Healio
11 October 2020
People with limited treatment options

Heavily Pretreated US HIV Patients Face Clinical Hurdles, Higher Death Risk

Editor's pick
NATAP
6 July 2020
New & experimental HIV treatments

ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available

Editor's pick
ViiV press release
3 July 2020
New & experimental HIV treatments

Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity

News
12 March 2020
New & experimental HIV treatments

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Editor's pick
ViiV Healthcare press release
13 January 2020
HIV treatment

Ibalizumab Factsheet

About HIV
January 2020
New & experimental HIV treatments

Capsid inhibitor GS-6207: potential for 6 monthly dosing for MDR HIV

Editor's pick
i-Base
16 December 2019
New & experimental HIV treatments

ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

Editor's pick
5 December 2019
New & experimental HIV treatments

Ibalizumab monoclonal antibody is effective in real-world use

News
7 October 2019
People with limited treatment options

Dramatic decline in proportion of people with extensive resistance to anti-HIV medications

News
6 August 2019
People with limited treatment options

Clinical and Economic Effects of Ibalizumab for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
2 August 2019